Early detection of anthracycline- and trastuzumab-induced cardiotoxicity: value and optimal timing of serum biomarkers and echocardiographic parameters doi.org/10.1002/ehf2.1…
English
Cardio-Oncology Pharmacist's Network
68 posts
Cardio-Oncology Pharmacist's Network
@CardioOncRxNet
The Cardio-Oncology Pharmacist Network is an independent group of Pharmacists involved in cardio-oncology practice and research
Katılım Nisan 2020
52 Takip Edilen215 Takipçiler
@Mayor_Jeff @fordnation @BarriePolice how is @MaximeBernier, who lives in Quebec, able to come to the @cityofbarrie and join protesters against lockdowns when interprovincial travel is prohibited? How was he not arrested?
English
Cardio-Oncology Pharmacist's Network retweetledi
#barrie folks please RT - @alectra_YorkSim is the account you want to follow for power info in Barrie, Simcoe County&York Region.
English
@tina_hemepharm might help with some heme protocols!
English
Cardio-Oncology Pharmacist's Network retweetledi
ECOS kicked off May with the launch of a 14-week #CME certificate course in #CardioOncology. The pre-course assessment for the 'Essentials of Cardio-oncology' course is now available. The 1st module featuring world experts in #CardioOnc goes live this Fri! bit.ly/2KZGaD3
English
Cardio-Oncology Pharmacist's Network retweetledi
Identification of anticancer drugs associated with atrial fibrillation - analysis of the WHO pharmacovigilance database academic.oup.com/ehjcvp/advance…
English
Cardio-Oncology Pharmacist's Network retweetledi
@TomasNeilan @sdent_duke @BCCare @ICOSociety We also have a manuscript under review that shows the long-term cardiovascular prognosis in women diagnosed with HF following trastuzumab is much better than other forms of HF: onlinejacc.org/content/75/11_…
More reasons to support 12 months of therapy.
English
Cardio-Oncology Pharmacist's Network retweetledi
@TomasNeilan @sdent_duke @BCCare @ICOSociety Agreed. For young women without pre-existing cardiovascular disease, the risk of dying from cardiovascular causes is negligible c/w the risk of dying from breast cancer: jamanetwork.com/journals/jamac…
English
Cardio-Oncology Pharmacist's Network retweetledi
Such an important paper @sdent_duke. 5 yr disease free survival drops from 94.1% to 82.4%, among young women with breast cancer. As cardiologists, let be sure we are not holding a key therapy due to an asymptomatic modest decline in EF. @BCCare @ICOSociety
Moira Rushton, MD, MPH@MoiraRushton
So proud to see this in print @JNCI_Now. More evidence to support a full year of trastuzumab for early stage Her2 positive breast ca. doi.org/10.1093/jnci/d…. @sdent_duke
English
"..less than one year of adjuvant trastuzumab, in patients with HER2+ early breast cancer, resulted in inferior clinical outcomes regardless of reason for treatment discontinuation"
Congrats to all of the authors of the paper! @sdent_duke
English
...does not improve cardiac safety, and may be detrimental if live-saving HER2 targeted therapy is prematurely discontinued"
English
Impact of stopping trastuzumab in early breast cancer: a population-based study in Ontario, Canada academic.oup.com/jnci/advance-a…
"The overall cardiac event rate in this study was low, suggesting that intensive cardiac monitoring of all patients treated with HER2 targeted therapy 1/
English
Great editorial on the debate of 6vs. 12 months of trastuzumab in @JNCI_Now The answer is clear: 12 months to maximize cancer outcomes. @sdent_duke academic.oup.com/jnci/advance-a…
English
Cardio-Oncology Pharmacist's Network retweetledi
@MoiraRushton @sdent_duke @JNCI_Now I have grown to appreciate the administrative dataset that Cancer Care Ontario has for analysis. Many thanks to the #pharmacists and #oncologists for their unwitting data entry that allows this analysis!
English
Cardio-Oncology Pharmacist's Network retweetledi
Proud to represent the UK in the first ever cohort of board-certified Cardio-Oncologists! Thanks to my family for all their support in enabling me to get to this stage! #CardioOnc #CardioOncology @ICOSociety @DLenihanICOS_MD @BCOSCardioOnc @BcsPresident @DrSarahClarke
English
Cardio-Oncology Pharmacist's Network retweetledi
Tomas G. Neilan, MD, MPH@TomasNeilan
Important paper, MI in cancer not consistently treated per standard guidelines. Medical and invasive treatment per guidelines yield survival advantages regardless of cancer stage and treatment. @onco_cardiology @dinubalanescu @PalaskasN internationaljournalofcardiology.com/article/S0167-…
Ashland, OH 🇺🇸 QHT
Cardio-Oncology Pharmacist's Network retweetledi
A second paper exploring cardiopulm fitness. Can it increase tolerance of ca tx & decrease cardio onc effects (short term vs longterm) if maintained before/during/after tx? I’m personally intrigued! #cardioonc @CardioOncology
Eric H Yang, MD@datsunian
Great review led by @MayoHemeOnc Ohad Oren, @MayoClinicCV @ChristinaDieli on the prognostic role of cardiopulm ex fitness in breast CA for @ACCinTouch. #cardioonc @sdent_duke @Dr_RShatsky @JenJordanPhD @UCLAJCCC @JeffHsuMD @DrPRao @mayocvonc @drbrowncares acc.org/latest-in-card…
English
Cardio-Oncology Pharmacist's Network retweetledi
Great review led by @MayoHemeOnc Ohad Oren, @MayoClinicCV @ChristinaDieli on the prognostic role of cardiopulm ex fitness in breast CA for @ACCinTouch. #cardioonc @sdent_duke @Dr_RShatsky @JenJordanPhD @UCLAJCCC @JeffHsuMD @DrPRao @mayocvonc @drbrowncares acc.org/latest-in-card…
Culver City, CA 🇺🇸 English
Cardio-Oncology Pharmacist's Network retweetledi
Important paper, MI in cancer not consistently treated per standard guidelines. Medical and invasive treatment per guidelines yield survival advantages regardless of cancer stage and treatment. @onco_cardiology @dinubalanescu @PalaskasN internationaljournalofcardiology.com/article/S0167-…
English